VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol
Amanda J. Hooper, Xuan Tang, John R. Burnett
Abstract
1. Just over two decades ago, a new member of the secretory subtilase family, neural apoptosis-regulated convertase 1 (NARC-1), now known as proprotein convertase subtilisin/kexin type 9 (PCSK9), w...
Topics & Concepts
PCSK9CRISPRCholesterolGenome editingBase (topology)ChemistryBiochemistryBiologyMedicineLDL receptorLipoproteinGeneMathematical analysisMathematicsLipoproteins and Cardiovascular HealthBiosimilars and Bioanalytical MethodsViral Infections and Immunology Research